All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

  TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Germline predisposition mutations and recurrent somatic mutations in Korean patients with ALL

By Sheetal Bhurke

Share:

Jun 24, 2021


The two most common malignancies in children are B-cell precursor and T-cell precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although genetic variations can be used to classify ALL, these are numerous and heterogenous. The 2016 revision to the World Health Organization (WHO) classification of ALL, added new provisional entities: BCR-ABL1-like (or Ph-like) ALL, iAMP21 (intrachromosomal amplification of chromosome 21), and early T-cell precursor ALL (ETP-ALL).1 In addition to somatic mutations, the WHO classification also included genes that are associated with predisposition to myeloid neoplasms including CEBPA, DDX41, RUNX1, ANKRD26, ETV6, and GATA2. There are also several syndromes that increase susceptibility to ALL including Li Fraumeni (TP53), and Wiskott Aldrich syndrome (WAS). Some genes (PAX5, ETV6, TP53, and IKZF1) associated with ALL are found to have both germline and somatic mutations, thus increasing the susceptibility to ALL. The ALL Hub has previously published an article describing the different genes impacted by germline mutations.

In a recently published study by Shin et al., the association of genetic alterations and predisposition to ALL in both pediatric and adult patients was investigated.1 The key findings are summarized below.

Methods

The study investigated genetic alterations in Korean patients with ALL using targeted gene panel sequencing.

Paired initial diagnosis and complete remission (CR) bone marrow samples from patients with ALL were selected.

Bone marrow slides of when the patients were in CR were used to detect germline mutations. Nearly a third of the patients had received allogeneic stem cell transplantation (allo-SCT), and in these patients, CR status bone marrow slides before transplantation were used to detect germline mutations. Slides with no apparent residual leukemic cells were used as control samples.

A gene panel consisting of 81 genes, known to be associated with 23 predisposition syndromes, was investigated. In addition to sequence variants, gene-level copy number variations (CNVs) were investigated.

Results

Baseline characteristics

In total, 65 pediatric (<20 years) and 28 adult patients with ALL were included. Patient characteristics are summarized in Table 1. The most common type of B-ALL in adults was BCR-ABL1, whereas in children was B-ALL not otherwise specified (NOS) and B-ALL with hyperdiploidy.

Table 1. Patient characteristics*

B-ALL, B-cell acute lymphoblastic leukemia; NOS, not otherwise specified; T-ALL, T-cell acute lymphoblastic leukemia.
*Data from Shin et al.1

Characteristic

Children
(n = 65)

Adults
(n = 28)

Sex, n

              Male

35

10

              Female

30

18

Diagnosis, n

              B-ALL, NOS

25

8

              B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1

2

11

              B-ALL with t(v;11q23.3); KMT2A rearranged

4

1

              B-ALL with t(12;21)(p13.2; q22.1); ETV6-RUNX1

9

0

              B-ALL with hyperdiploidy

16

1

              B-ALL with t(1;19)(q23; p13.3); TCF3-PBX1

2

2

              T-ALL

5

5

              Early T-cell precursor acute leukemia

2

0

B-ALL cytogenic risk group, n

              Good

26

2

              Intermediate

26

9

              High

6

12

Germline sequence variants

Only one pathogenic TP53 variant (Accession: NM_000546.5) was identified in an adult patient with B-ALL NOS. A known CNV, CASP10 (Accession: NM_032977.3), was identified in one pediatric patient with B-ALL NOS.

Five heterozygous autosomal recessive (AR) primary immunodeficiency disorder (PID)-associated gene variants were identified in five other patients (as shown in Table 2).

Table 2. Germline sequence variants*

AR, autosomal recessive; F, female; M, male.
*Data from Shin et al.1

Patient ID

Age/Sex

Gene

% variant

Syndrome

ALL0009

51/F

TP53

40.3

Li-Fraumeni syndrome

ALL0067

18/M

CASP10

Autoimmune lymphoproliferative syndrome, Type II

ALL0077

10/M

TYK2

40.2

Immunodeficiency 35, AR

ALL0053

2/M

IL12RB1

50.7

Immunodeficiency 30, AR

ALL0060

40/M

LPIN2

44.0

Majeed syndrome, AR

ALL0071

2/F

CTC1

47.0

Dyskeratosis congenital, AR

ALL0021

2/M

LIG4

42.6

LIG4 syndrome, AR

Somatic sequence variants

A total of 197 somatic sequence variants and 223 somatic CNV were identified. The most common somatic sequence variants and CNVs in B-ALL and T-ALL patients are shown in Table 3. All NRAS and KRAS variants were previously reported variants. The majority of the FLT3 variants were known variants in hematological malignancies, and about 50% of the PAX5 variants were also recurrent variants.

Table 3. Somatic sequence variants*

B-ALL, B-cell acute lymphoblastic leukemia; CNV, copy number variations; T-ALL, T-cell acute lymphoblastic leukemia.
*Data from Shin et al.1

Sequence variant

%

Somatic sequence variant in T-ALL

              NOTCH1

50

              FBXW7

25

              IL7R

25

              NRAS

25

              DNMT3A

17

              PHF6

17

              GATA3

17

Somatic sequence variant in B-ALL

              NRAS

17

              FLT3

14

              KRAS

9

              SETD2

7

              PAX5

6

              CREBBP

6

CNV in T-ALL

              CDKN2A/B

50

              CRLF2

17

              GATA3

8

              CSF2RA

8

              BCOR

8

CNV in B-ALL

              CDKN2A/B

31

              IKZF1

16

              ETV6

12

              ERG

12

              RB1

11

IKZF1 alterations were present in 15 B-ALL patients:

  • Seven patients had B-ALL with BCR-ABL1 and all had an IKZF1 deletion.
  • Out of seven B-ALL patients with NOS, six had an IKZF1 deletion and one had a IKZF1 frameshift mutation.
  • Only one patient with T-ALL had an IKZF1 alteration (missense mutation).
  • Three B-ALL patients with BCR-ABL1 and two with B-ALL NOS with IKZF1 deletions also had deletion of PAX5.
  • The frequency of IKZF1 deletion was higher in the adult high-risk cytogenic group (6/12, 50%) compared with the overall B-ALL group (13/81, 16%). This may be due to most adult cases (11/12) being ALL with BCR-ABL1.
  • The study also found high concordance (83.7%) between fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) for CDKN2A/B.
  • Statistically significant differences were seen in the overall survival (OS) and relapse-free survival (RFS) (p < 0.5) in childhood ALL compared with adult ALL.
  • The adverse effect of IKZF1 on OS and RFS was seen only in childhood ALL. No other genes had a consistent clinical effect in either childhood or adult ALL.

Conclusion

The study found recurrent somatic alterations in Korean T-ALL patients, consistent with previous studies. IKZF1 alteration was associated with an adverse effect on OS and RFS in childhood ALL. Six patients had variants in six genes associated with PID. Of the 81 genes associated with 23 predisposition syndromes, only one predisposition germline mutation (TP53) was identified. Taken together, the results indicate a low probability of germline mutation predisposition to ALL in Korean patients. However, the study was limited by the number of patients with early T-cell precursor ALL, and further studies should explore this patient group.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?